European Commission approval for AbbVie’s psoriasis treatment

AbbVie has announced that the European Commission (EC) has approved its interleukin-23 (IL-23) inhibitor Risankizumab, for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy. The EC gave approval following results from four Phase III studies, ultIMMa-1, ultIMMa-2, IMMvent and IMMhance which assessed more than 2,000 patients

Continue Reading